Developer docs
API playgroundTry for free, no card

Search company profiles

WeTrials

Full company profile

uuid0024v1q

Namestring
WeTrials
Legal namestring
WeTrials
Websiteurl
wetrials.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

WeTrials is an AI-powered digital health platform that simplifies the clinical trial journey for individuals diagnosed with cancer and their care partners. Founded in 2022 and headquartered in Mechanicsburg, Pennsylvania (with operating presence in Philadelphia), the company addresses the difficulty patients face in discovering, evaluating, and understanding cancer clinical trials. Its primary focus is on brain cancer, breast cancer, lung cancer, pediatric cancer, and prostate cancer. The platform centralizes clinical trial information, uses AI to translate complex trial language into accessible explanations, and delivers personalized trial matching based on patient diagnosis and preferences.

The core product is the WeTrials AI Patient Engagement Platform, supplemented by iOS and Android mobile applications, a Learning Center with condition-specific educational content, The Caregiver Chronicles video podcast series, free checklists and guides, and a beta WeTrials AI Assistant for conversational patient support. Technology features include generative AI for patient Q&A and language simplification, a recommendation engine for trial matching, knowledge retrieval tied to molecular diagnostics, and process automation for enrollment workflows. A technically notable integration embeds WeTrials trial links directly within GenomOncology's GO Genomic Reports, enabling a workflow from Belay Diagnostics' Summit 2.0 liquid biopsy output through to trial enrollment for CNS cancer patients.

The business model is free to consumers; revenue is generated through institutional partnerships. Named partners include Beat Childhood Cancer at Penn State College of Medicine (a 50+ hospital pediatric research consortium spanning North America, South America, and Europe), the American Brain Tumor Association (white-labeled Clinical Trial Finder on the ABTA website), GenomOncology and Belay Diagnostics (genomic report integration), the Glioblastoma Support Network (co-founders sit on the GSN board), and the Canadian Cancer Society (joint webinar work). WeTrials operates under HIPAA and CCPA compliance. The company is led by co-founders Romeo De Leon (CEO) and Dr. Alireza Mansouri, MD (CMO, named Penn State Health Physician of the Year in 2025), with a small team of software, product, clinical research, and digital marketing staff.

Short descriptiontext

WeTrials is an AI-powered digital health platform that simplifies clinical trial discovery and enrollment for cancer patients and caregivers, particularly in brain, breast, lung, pediatric, and prostate cancers, through institutional partnerships with advocacy groups and research consortia.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMechanicsburg, United States
HQ citystring
Mechanicsburg
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical trial discovery, patient engagement software, cancer clinical trials, clinical trial matching, healthcare navigation tools
Industry3 codes
PRIMARYHLAGACAI
eConsent & Patient Engagement at Site
SECONDARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLACAOAI
Clinical Trial Analytics, Risk-Based Monitoring (RBM) & Quality Management
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
NAICS code3 codes
  • Computer Systems Design and Related Services54151
  • Web Search Portals, Libraries, Archives, and Other Information Services519
  • Professional, Scientific, and Technical Services54
SIC code1 code
  • Services-Health Services8000
Product category
Clinical Trial Patient Engagement Platform
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Platform Services to Healthcare Institutions
TypeSubscription Recurring
Description

WeTrials provides its AI-powered patient engagement platform to healthcare institutions, research consortia, and advocacy organizations. The platform appears to be offered at no cost to patients while generating revenue through partnerships with healthcare organizations, clinical trial sponsors, and research institutions.

wetrials.com
2Institutional Partnerships
TypeProfessional Services
Description

Revenue generated through partnerships with institutions, advocacy groups, and healthcare organizations that use WeTrials to connect patients with clinical trials. Services include technology access, tools, resources, and support for patient engagement.

wetrials.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Marketing or Sales, Operations
GTM typeB2B and B2C
B2B and B2C
Offering typeSoftware
Software
Core offering1 text field

WeTrials operates an AI-powered patient engagement platform that helps cancer patients and caregivers discover, understand, and navigate clinical trial opportunities. The platform centralizes study information across brain, breast, lung, pediatric, and prostate cancers, translates complex trial language into understandable terms, and provides personalized trial matching, educational content, and support resources. It is offered free to patients and is distributed through white-label embedded integrations with advocacy groups, genomic diagnostic reports, and research consortia.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

WeTrials is a clinical trial patient engagement platform consisting of a core AI-powered patient engagement platform and multiple integrated modules. The core WeTrials AI Patient Engagement Platform provides simplified trial discovery, AI-powered matching, and personalized support. Supporting products include the ABTA Clinical Trial Finder (white-labeled discovery tool), WeTrials Learning Center (educational content), The Caregiver Chronicles (video series), Checklists & Guides (patient resources), Mobile App (iOS/Android), WeTrials AI Assistant (beta chatbot), and specialized tools for Clinicians and Advocacy Groups. The platform targets multiple cancer types: brain cancer, breast cancer, lung cancer, pediatric cancer, and prostate cancer.

Product and service3 records
1WeTrials AI Patient Engagement Platform
CategoryClinical Trial Patient Engagement Platform
Description

AI-powered platform that helps cancer patients and families discover, understand, and navigate clinical trial opportunities. Centralizes study information, provides simplified trial language, and offers personalized educational and support resources across brain, breast, lung, pediatric, and prostate cancers. Distributed to patients free of charge and licensed to healthcare institutions and research consortia.

2ABTA Clinical Trial Finder
CategoryClinical Trial Discovery Tool (Embedded)
Description

White-labeled clinical trial discovery tool powered by WeTrials and embedded on the American Brain Tumor Association website. Provides brain tumor patients and families with intuitive trial summaries, advanced filtering, and streamlined navigation to find relevant clinical trials.

3WeTrials Mobile App
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1Beat Childhood Cancer at Penn State College of Medicine
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-07-07
Description

Beat Childhood Cancer, an international pediatric cancer research consortium with 50+ hospitals and research institutions across North America, South America, and Europe, has implemented the WeTrials AI-powered patient engagement platform. Families can access simplified study information, personalized educational experiences, and AI-powered engagement tools to discover and navigate pediatric cancer clinical trials.

wetrials.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-03-10
Description

Strategic partnership with GenomOncology to help CNS cancer patients access and enroll in clinical trials faster. The collaboration embeds a direct link to WeTrials' platform within GenomOncology's GO Genomic Reports, creating a seamless pathway from molecular diagnosis to trial enrollment. Initial focus on CNS cancer patients tested through Belay Diagnostics, with plans to expand to additional diagnostic partners and cancer types.

3Belay Diagnostics
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-03-10
Description

Partnership expands on existing GenomOncology-Belay Diagnostics relationship. Belay's Summit 2.0 liquid biopsy test workflow integrates with GenomOncology's GO Pathology Workbench, and the GO Genomic Report now includes direct link to WeTrials platform. This creates integrated pathway from molecular diagnosis to trial enrollment for CNS cancer patients.

wetrials.com
4American Brain Tumor Association (ABTA)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-12
Description

Partnership to advance clinical trial accessibility for brain tumor patients. WeTrials launched the ABTA Clinical Trial Finder—a patient-centered tool live on the ABTA website that helps patients and families explore clinical trials with simplified summaries, advanced filtering, and intuitive navigation. Combined ABTA's community roots with WeTrials' technology platform.

wetrials.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-03-15
Description

WeTrials co-founders Dr. Alireza Mansouri and Romeo De Leon joined the GSN board as Directors. Partnership aims to enhance support, resources, and hope for individuals and families impacted by glioblastoma. Combines WeTrials' expertise in clinical trials with GSN's patient support framework.

Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2023-12-14
Description

Collaborated with Canadian Cancer Society to host webinar 'Demystifying Clinical Trials for Indigenous People' presented by Dr. Alireza Mansouri. Webinar focused on empowering Indigenous communities with knowledge about clinical trials for brain tumors and glioblastoma.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Deep 6 AI
TypeDirect peer
Description

AI-native clinical trial matching platform that uses EHR and structured patient data to accelerate enrollment. Closest direct competitor to WeTrials' core AI trial-matching thesis, though focused on site/sponsor workflows rather than direct-to-patient engagement.

2Mendel
TypeDirect peer
Description

AI platform for matching patients to clinical trials from unstructured medical records, primarily serving sponsors and CROs. Comparable to WeTrials' AI matching layer but with a B2B-first commercial model and a broader therapeutic scope.

3Antidote (formerly TrialReach)
TypeDirect peer
Description

Patient-facing clinical trial matching platform that partners with patient advocacy groups and pharma sponsors. Most analogous business model to WeTrials' advocacy-embedded, patient-first approach.

TypeDirect peer
Description

AI-driven oncology clinical trial enrollment company that pre-screens cancer patients against trial criteria. Directly comparable to WeTrials in the oncology niche and in the use of AI for patient-trial matching.

TypeDirect peer
Description

Digital health platform offering AI-powered clinical trial matching and patient recruitment, with both consumer and provider-facing surfaces. Comparable in functionality and target users to WeTrials' platform.

TypeDirect peer
Description

AI platform that matches cancer patients to treatment options including clinical trials, with deep oncology focus. Closest peer to WeTrials in terms of cancer-specific AI matching and patient engagement.

TypeDirect peer
Description

Patient-centric clinical trial matching service that combines AI tools with human navigators, partnering with advocacy organizations. Highly comparable to WeTrials' patient-first, advocacy-embedded model.

TypeBroad incumbent
Description

Large, established clinical trial technology platform (EDC, CTMS, eCOA, RTSM). Represents the enterprise incumbent whose broader portfolio can absorb and bundle trial-matching functionality, competing indirectly with WeTrials at the sponsor level.

TypeBroad incumbent
Description

Global CRO and life sciences technology provider with extensive clinical trial matching and patient recruitment capabilities. Competes with WeTrials indirectly at the pharma-sponsor layer with vastly greater scale and data assets.

TypeEmerging player
Description

Health navigation platform historically focused on guiding employees to care options; adjacent to WeTrials' patient-navigation thesis and could expand into clinical trial discovery as a feature.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

WeTrials

Clinical Trial Patient Engagement Platformwetrials.com

WeTrials is an AI-powered digital health platform that simplifies clinical trial discovery and enrollment for cancer patients and caregivers, particularly in brain, breast, lung, pediatric, and prostate cancers, through institutional partnerships with advocacy groups and research consortia.

What WeTrials does

WeTrials is an AI-powered digital health platform that simplifies the clinical trial journey for individuals diagnosed with cancer and their care partners. Founded in 2022 and headquartered in Mechanicsburg, Pennsylvania (with operating presence in Philadelphia), the company addresses the difficulty patients face in discovering, evaluating, and understanding cancer clinical trials. Its primary focus is on brain cancer, breast cancer, lung cancer, pediatric cancer, and prostate cancer. The platform centralizes clinical trial information, uses AI to translate complex trial language into accessible explanations, and delivers personalized trial matching based on patient diagnosis and preferences.

The core product is the WeTrials AI Patient Engagement Platform, supplemented by iOS and Android mobile applications, a Learning Center with condition-specific educational content, The Caregiver Chronicles video podcast series, free checklists and guides, and a beta WeTrials AI Assistant for conversational patient support. Technology features include generative AI for patient Q&A and language simplification, a recommendation engine for trial matching, knowledge retrieval tied to molecular diagnostics, and process automation for enrollment workflows. A technically notable integration embeds WeTrials trial links directly within GenomOncology's GO Genomic Reports, enabling a workflow from Belay Diagnostics' Summit 2.0 liquid biopsy output through to trial enrollment for CNS cancer patients.

The business model is free to consumers; revenue is generated through institutional partnerships. Named partners include Beat Childhood Cancer at Penn State College of Medicine (a 50+ hospital pediatric research consortium spanning North America, South America, and Europe), the American Brain Tumor Association (white-labeled Clinical Trial Finder on the ABTA website), GenomOncology and Belay Diagnostics (genomic report integration), the Glioblastoma Support Network (co-founders sit on the GSN board), and the Canadian Cancer Society (joint webinar work). WeTrials operates under HIPAA and CCPA compliance. The company is led by co-founders Romeo De Leon (CEO) and Dr. Alireza Mansouri, MD (CMO, named Penn State Health Physician of the Year in 2025), with a small team of software, product, clinical research, and digital marketing staff.

WeTrials firmographics

Firmographics
Name
WeTrials
Legal name
WeTrials
Website
https://wetrials.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
1–10 employees
Short description
WeTrials is an AI-powered digital health platform that simplifies clinical trial discovery and enrollment for cancer patients and caregivers, particularly in brain, breast, lung, pediatric, and prostate cancers, through institutional partnerships with advocacy groups and research consortia.
Ownership category
akta.pro rank

WeTrials industry classification

Industry
Product category
Clinical Trial Patient Engagement Platform
NAICS
Computer Systems Design and Related Services (54151), Web Search Portals, Libraries, Archives, and Other Information Services (519), Professional, Scientific, and Technical Services (54)
SIC
Services-Health Services (8000)
akta.pro industry
PRIMARYHLAGACAI
eConsent & Patient Engagement at Site
SECONDARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLACAOAI
Clinical Trial Analytics, Risk-Based Monitoring (RBM) & Quality Management
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)

Keywords

  • Clinical trial discovery
  • Patient engagement software
  • Cancer clinical trials
  • Clinical trial matching
  • Healthcare navigation tools

Where WeTrials is headquartered

Location

Headquarters

HQ city
Mechanicsburg
HQ country
United States
HQ region
North America

Offices1 record

Markets served

WeTrials business model

Business model
GTM type
B2B and B2C
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

  1. Platform Services to Healthcare Institutions: WeTrials provides its AI-powered patient engagement platform to healthcare institutions, research consortia, and advocacy organizations. The platform appears to be offered at no cost to patients while generating revenue through partnerships with healthcare organizations, clinical trial sponsors, and research institutions.
  2. Institutional Partnerships: Revenue generated through partnerships with institutions, advocacy groups, and healthcare organizations that use WeTrials to connect patients with clinical trials. Services include technology access, tools, resources, and support for patient engagement.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels6 records

WeTrials product offering

Product offering

Core offering

WeTrials operates an AI-powered patient engagement platform that helps cancer patients and caregivers discover, understand, and navigate clinical trial opportunities. The platform centralizes study information across brain, breast, lung, pediatric, and prostate cancers, translates complex trial language into understandable terms, and provides personalized trial matching, educational content, and support resources. It is offered free to patients and is distributed through white-label embedded integrations with advocacy groups, genomic diagnostic reports, and research consortia.

Product overview

WeTrials is a clinical trial patient engagement platform consisting of a core AI-powered patient engagement platform and multiple integrated modules. The core WeTrials AI Patient Engagement Platform provides simplified trial discovery, AI-powered matching, and personalized support. Supporting products include the ABTA Clinical Trial Finder (white-labeled discovery tool), WeTrials Learning Center (educational content), The Caregiver Chronicles (video series), Checklists & Guides (patient resources), Mobile App (iOS/Android), WeTrials AI Assistant (beta chatbot), and specialized tools for Clinicians and Advocacy Groups. The platform targets multiple cancer types: brain cancer, breast cancer, lung cancer, pediatric cancer, and prostate cancer.

Differentiator

Problem solved

Functional benefit

Products and services

  • WeTrials AI Patient Engagement Platform AI-powered platform that helps cancer patients and families discover, understand, and navigate clinical trial opportunities. Centralizes study information, provides simplified trial language, and offers personalized educational and support resources across brain, breast, lung, pediatric, and prostate cancers. Distributed to patients free of charge and licensed to healthcare institutions and research consortia.
  • ABTA Clinical Trial Finder White-labeled clinical trial discovery tool powered by WeTrials and embedded on the American Brain Tumor Association website. Provides brain tumor patients and families with intuitive trial summaries, advanced filtering, and streamlined navigation to find relevant clinical trials.
  • WeTrials Mobile App

Companies that use WeTrials

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles4 records

WeTrials technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

WeTrials partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • Beat Childhood Cancer at Penn State College of MedicinecoreStrategic or Co-development Partner · 7 July 2026Beat Childhood Cancer, an international pediatric cancer research consortium with 50+ hospitals and research institutions across North America, South America, and Europe, has implemented the WeTrials AI-powered patient engagement platform. Families can access simplified study information, personalized educational experiences, and AI-powered engagement tools to discover and navigate pediatric cancer clinical trials.
  • GenomOncologycoreTechnology or Integration · 10 March 2026Strategic partnership with GenomOncology to help CNS cancer patients access and enroll in clinical trials faster. The collaboration embeds a direct link to WeTrials' platform within GenomOncology's GO Genomic Reports, creating a seamless pathway from molecular diagnosis to trial enrollment. Initial focus on CNS cancer patients tested through Belay Diagnostics, with plans to expand to additional diagnostic partners and cancer types.
  • Belay DiagnosticscoreTechnology or Integration · 10 March 2026Partnership expands on existing GenomOncology-Belay Diagnostics relationship. Belay's Summit 2.0 liquid biopsy test workflow integrates with GenomOncology's GO Pathology Workbench, and the GO Genomic Report now includes direct link to WeTrials platform. This creates integrated pathway from molecular diagnosis to trial enrollment for CNS cancer patients.
  • American Brain Tumor Association (ABTA)coreStrategic or Co-development Partner · 12 September 2025Partnership to advance clinical trial accessibility for brain tumor patients. WeTrials launched the ABTA Clinical Trial Finder—a patient-centered tool live on the ABTA website that helps patients and families explore clinical trials with simplified summaries, advanced filtering, and intuitive navigation. Combined ABTA's community roots with WeTrials' technology platform.
  • Glioblastoma Support NetworkcoreStrategic or Co-development Partner · 15 March 2024WeTrials co-founders Dr. Alireza Mansouri and Romeo De Leon joined the GSN board as Directors. Partnership aims to enhance support, resources, and hope for individuals and families impacted by glioblastoma. Combines WeTrials' expertise in clinical trials with GSN's patient support framework.
  • Canadian Cancer SocietyminorGTM or Marketing Partner · 14 December 2023Collaborated with Canadian Cancer Society to host webinar 'Demystifying Clinical Trials for Indigenous People' presented by Dr. Alireza Mansouri. Webinar focused on empowering Indigenous communities with knowledge about clinical trials for brain tumors and glioblastoma.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

WeTrials competitors and assessment

Company assessment

Direct peers

  • Deep 6 AI: AI-native clinical trial matching platform that uses EHR and structured patient data to accelerate enrollment. Closest direct competitor to WeTrials' core AI trial-matching thesis, though focused on site/sponsor workflows rather than direct-to-patient engagement.
  • Mendel: AI platform for matching patients to clinical trials from unstructured medical records, primarily serving sponsors and CROs. Comparable to WeTrials' AI matching layer but with a B2B-first commercial model and a broader therapeutic scope.
  • Antidote (formerly TrialReach): Patient-facing clinical trial matching platform that partners with patient advocacy groups and pharma sponsors. Most analogous business model to WeTrials' advocacy-embedded, patient-first approach.
  • Massive Bio: AI-driven oncology clinical trial enrollment company that pre-screens cancer patients against trial criteria. Directly comparable to WeTrials in the oncology niche and in the use of AI for patient-trial matching.
  • TrialX: Digital health platform offering AI-powered clinical trial matching and patient recruitment, with both consumer and provider-facing surfaces. Comparable in functionality and target users to WeTrials' platform.
  • xCures: AI platform that matches cancer patients to treatment options including clinical trials, with deep oncology focus. Closest peer to WeTrials in terms of cancer-specific AI matching and patient engagement.
  • Clara Health: Patient-centric clinical trial matching service that combines AI tools with human navigators, partnering with advocacy organizations. Highly comparable to WeTrials' patient-first, advocacy-embedded model.

Broad incumbents

  • Medidata (Dassault Systèmes): Large, established clinical trial technology platform (EDC, CTMS, eCOA, RTSM). Represents the enterprise incumbent whose broader portfolio can absorb and bundle trial-matching functionality, competing indirectly with WeTrials at the sponsor level.
  • IQVIA: Global CRO and life sciences technology provider with extensive clinical trial matching and patient recruitment capabilities. Competes with WeTrials indirectly at the pharma-sponsor layer with vastly greater scale and data assets.

Emerging players

  • Castlight Health: Health navigation platform historically focused on guiding employees to care options; adjacent to WeTrials' patient-navigation thesis and could expand into clinical trial discovery as a feature.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

WeTrials social profiles

Digital presence

WeTrials compliance and trust

Trust signal

Compliance2 records

WeTrials financial estimates

Financial estimate

Revenue estimate

Valuation estimate

WeTrials leadership team

Management profile

Number of profiles

Profiles4 records

WeTrials funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

WeTrials M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about WeTrials

What does WeTrials do?

WeTrials operates an AI-powered patient engagement platform that helps cancer patients and caregivers discover, understand, and navigate clinical trial opportunities. The platform centralizes study information across brain, breast, lung, pediatric, and prostate cancers, translates complex trial language into understandable terms, and provides personalized trial matching, educational content, and support resources. It is offered free to patients and is distributed through white-label embedded integrations with advocacy groups, genomic diagnostic reports, and research consortia.

Is WeTrials a public or private company?

WeTrials is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was WeTrials founded?

WeTrials was founded in 2021. It employs 1 to 10 people.

Where is WeTrials based?

WeTrials is headquartered in Mechanicsburg, United States, in the North America region.

How does WeTrials make money?

Two revenue lines are on record. Platform Services to Healthcare Institutions are the primary driver. The others are institutional Partnerships.

Who are WeTrials's main competitors?

Direct peers on record are Deep 6 AI, Mendel, Antidote (formerly TrialReach), Massive Bio, TrialX, xCures and Clara Health. Broad incumbents are Medidata (Dassault Systèmes) and IQVIA. Castlight Health is listed as an emerging player.

Does WeTrials have an API?

No public API is recorded for WeTrials.

What industry is WeTrials in?

WeTrials's product category is Clinical Trial Patient Engagement Platform. Its primary akta.pro industry code is HLAGACAI, eConsent & Patient Engagement at Site, with a secondary code of HLAGAJAM, Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF). Its NAICS code is 54151 and its SIC code is 8000.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Penn State Health NewsBeat Childhood Cancer at Penn State College of Medicine launches WeTrials AI patient engagement platformBeat Childhood Cancer, a pediatric cancer research consortium, has launched the WeTrials AI-powered patient engagement platform to help families discover and understand clinical trial opportunities. This collaboration aims to bridge the gap between research and patients by providing simplified study information and personalized support tools across its international network.NewswiseBeat Childhood Cancer at Penn State College of Medicine launches WeTrials AI patient engagement platformBeat Childhood Cancer, an international pediatric cancer research consortium based at Penn State College of Medicine with more than 50 hospitals and research institutions across North America, South America and Europe, announced it has implemented the WeTrials AI-powered patient engagement platform. The platform centralizes study information, educational and support resources, and AI tools to help families discover and navigate pediatric cancer clinical trials. WeTrials said multilingual capabilities and additional AI features may follow.PR NewswireGenomOncology Announces Strategic Partnership with WeTrials to Accelerate Clinical Trial Enrollment for CNS Cancer PatientsGenomOncology announced a strategic partnership with WeTrials to help CNS cancer patients access and enroll in clinical trials faster by embedding a direct link to WeTrials' platform within GenomOncology's GO Genomic Reports. The collaboration expands on GenomOncology's existing partnership with Belay Diagnostics, whose Summit™ 2.0 liquid biopsy test workflow will serve as the foundation for the integrated pathway from molecular diagnosis to trial enrollment. The initial phase will focus on CNS cancer patients tested through Belay Diagnostics, with plans to expand to additional diagnostic partners and cancer types over time.